

infikovaných. Vzhledem k tomu, že pacienti léčení ART mají v dnešní době téměř normální délku života a vedlejší účinky novějších kombinací antiretrovirotik jsou významně

menší, nové léčebné modality musí překonat relativně vysoký standard současné léčby infekce HIV. Dlouhodobě působící léčiva, nové technologie a nové léčebné strategie mohou

nalézt uplatnění nejen v léčbě infekce HIV, ale i v léčbě a eliminaci jiných onemocnění jako je tuberkulóza, malárie, hepatitida B, hepatitida C a další (28).

LITERATURA

1. Peterson TA, MacLean AG. Current and future therapeutic strategies for lentiviral eradication from macrophage reservoirs. *Neuroimmune Pharmacol.* 2019;14(1):68-93.
 2. Margolis DM, Koup RA, Ferrari G. HIV antibodies for treatment of HIV infection. *Immunol Rev.* 2017;275(1):313-323.
 3. Thoueille P, Choong E, Cavassini M, et al. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. *J Antimicrob Chemother.* 2022;77(2):290-302.
 4. Snopková S, Rozsypal H, Aster V, et al. Doporučený postup péče o dospělě infikované HIV a postexpozici profylaxe infekce HIV. *Klin mikrobiol inf lék.* 2019;3:96-119.
 5. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV [Internet]. Januar 20, 2022. Developed by the DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents – A Working Group of the Office of AIDS Research Advisory Council (OARAC). [cited 2022 Feb 10]; Available from: <https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv/whats-new-guidelines>.
 6. Snopková S, Husa P. Moderní léčba HIV. *PROFI Medicína.* 2021;13-14:16-22.
 7. Henderson LJ, Reoma LB, Kovacs JA, et al. Advances toward curing HIV-1 infection in tissue reservoirs. *J Virol [Internet].* 2020; 94:e00375-19 [cited 2022 Feb 15]. Available from: <https://doi.org/10.1128/JVI.00375-19>.
 8. Cao S, Woodrow KA. Nanotechnology approaches to eradicating HIV reservoirs. *Eur J Pharm Biopharm.* 2019;138:48-63.
 9. Lu DY, Wu HY, Yarla NS, et al. HAART in HIV/AIDS treatment: future trends. *Infect Disord Drug Targets.* 2018;18(1):15-22.
 10. Paiardini M, Dhodapkar K, Harper J, et al. Editorial: HIV and cancer immunotherapy: similar challenges and converging approaches. *Front Immunol [Internet].* 2020;11:519 [cited 2022 Feb 15]. Available from: DOI: 10.3389/fimmu.2020.00519.
 11. Kirtane AR, Langer R, Traverso G. Past, present, and future drug delivery systems for antiretrovirals. *J Pharm Sci.* 2016;105(12):3471-3482.
 12. Alrubayyi A, Ogbe A, Moreno Cubero E, et al. Harnessing natural killer cell innate and adaptive traits in HIV infection. *Front Cell Infect Microbiol [Internet].* 2020;10:395 [cited 2022 Feb 10]. Available from: DOI: 10.3389/fcimb.2020.00395.
 13. Liu R, Simonetti FR, Ho YC. The forces driving clonal expansion of the HIV-1 latent reservoir. *Virol J [Internet].* 2020;17:4 [cited 2022 Feb 10]. Available from: <https://doi.org/10.1186/s12985-019-1276-8>.
 14. Hong FF, Mellors JW. Changes in HIV reservoirs during long-term antiretroviral therapy. *Curr Opin HIV AIDS.* 2015;10(1):43-48.
 15. Margolis DM, Archin NM, Cohen MS, et al. Curing HIV: seeking to target and clear persistent infection. *Cell.* 2020;181(1):189-206.
 16. Trivedi J, Mahajan D, Jaffe RJ, et al. Recent advances in the development of integrase inhibitors for HIV treatment. *Curr HIV/AIDS Rep.* 2020;17(1):63-75.
 17. Perreau M, Banga R, Pantaleo G. Target immune interventions for an HIV-1 cure. *Trends Mol Med [Internet].* 2017;23(10) [cited 2022 Feb 10]. Available from: <http://dx.doi.org/10.1016/j.molmed.2017.08.006>.
 18. Vieillard V, Gharakhanian S, Lucar O, et al. Perspectives for immunotherapy: which applications might achieve an HIV functional cure? *Oncotarget.* 2016;7(25):38946-38958.
 19. Ahlenstiel CL, Symonds G, Kent SJ, et al. Block and lock HIV cure strategies to control the latent reservoir. *Front Cell*

Infect Microbiol [Internet]. 2020;10:424 [cited 2022 Feb 10]. Available from: <https://doi.org/10.3389/fcimb.2020.00424>.
 20. Ait-Ammar A, Kula A, Darcis G, et al. Current status of latency reversing agents facing the heterogeneity of HIV-1 cellular and tissue reservoirs. *Front Microbiol [Internet].* 2020;10:3060 [cited 2022 Feb 10]. Available from: DOI: 10.3389/fmicb.2019.03060.
 21. Grau-Expo'sito J, Luque-Ballesteros L, Navarro J, et al. Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations. *PLoS Pathog [Internet].* 2019;15(8): e1007991 [cited 2022 Feb 10]. Available from: <https://doi.org/10.1371/journal.ppat.1007991>.
 22. Bowen A, Sweeney EE, Fernandes R. Nanoparticle-based immunoengineered approaches for combating HIV. *Front Immunol [Internet].* 2020;11:789 [cited 2022 Jan 12]. Available from: DOI: 10.3389/fimmu.2020.00789.
 23. Oti VB. Nanoparticles and its implications in HIV/AIDS therapy. *Curr Drug Discov Technol.* 2020;17(4):448-456.
 24. Patil V, Patel A. Biodegradable nanoparticles: a recent approach and applications. *Current Drug Targets.* 2020; 21(16):1722-1732.
 25. Kevadiya BD, Ottemann B, Mukadam IZ, et al. Rod-shape theranostic nanoparticles facilitate antiretroviral drug biodistribution and activity in human immunodeficiency virus susceptible cells and tissues. *Theranostics.* 2020;10(2):630-656.
 26. Edagwa B, McMillan JE, Sillman B, et al. Long-acting slow effective release antiretroviral therapy. *Expert Opin Drug Deliv.* 2017;14(11):1281-191.
 27. Soriano V, Fernandez-Montero JV, Benitez-Gutierrez L, et al. Dual antiretroviral therapy for HIV infection. *Expert Opin Drug Saf.* 2017;16(8):923-932.
 28. Flexner C, Owen A, Siccardi M, et al. Long-acting drugs and formulations for the treatment and prevention of HIV infection. *Int J Antimicrob Agents [Internet].* 2021;57(1):106220 [cited 2022 Jan 12]. Available from: DOI: 10.1016/j.ijantimicag.2020.106220.
 29. Cambou MC, Landovitz RJ. Novel antiretroviral agents. *Curr HIV/AIDS Rep.* 2020;17:118-124.
 30. Schurmann D, Rudd DJ, Zhang S, et al. Lancet HIV [Internet]. 2020;7(3):e164-e172 [cited 2022 Jan 12]. Available from: DOI: 10.1016/S2352-3018(19)30372-8.
 31. Home – ClinicalTrials.gov [cited 2022 Jan 12]. The United States National Library of Medicine at the National Institutes of Health. Available from: www.clinicaltrials.gov.
 32. Highleyman L. Trials of long-acting islatravir for HIV treatment and prevention placed on hold. In: *Aidsmap.com [Internet].* 2021 Dec 21. [cited 2022 Jan 12]. Available from: <https://www.aidsmap.com/news/dec-2021/trials-long-acting-islatravir-hiv-treatment-and-prevention-placed-on-hold>.
 33. Margot N, Ram R, Rhee M, et al. Absence of lenacavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes. *Antimicrob Agents Chemother [Internet].* 2021;65:e02057-20 [cited 2022 Jan 12]. Available from: <https://doi.org/10.1128/AAC.02057-20>.
 34. Dvory-Sobol H, Shaik N, Callebaut C, et al. Lenacavir: a first-in-class HIV-1 capsid inhibitor. *Curr Opin HIV AIDS.* 2022;17(1):15-21.
 35. Menéndez-Arias L, Delgado R. Update and latest advances in antiretroviral therapy. *Trends Pharmacol Sci.* 2022;43(1):16-29.
 36. Terry M. FDA places hold on Gilead HIV trials over vial qu-

ality concerns. In: *BioSpace.com [Internet].* 2021 Dec 22. [cited 2022 Jan 12]. Available from: <https://www.biospace.com/article/fda-places-clinical-hold-on-use-of-glass-vials-in-gilead-s-hiv-trials/>.
 37. Barin F, Stefic K. Anticorps neutralisants tri-spécifiques. Une solution pour l'immunoprofylaxie ou l'immunothérapie anti-VIH ? *Med Sci.* 2018;34:109-128.
 38. Wang Q, Zhang L. Broadly neutralizing antibodies and vaccine design against HIV-1 infection. *Front Med.* 2020;14(1):30-42.
 39. Haynes BF, Burtzon DR, Mascola JR. Multiple roles for HIV broadly neutralizing antibodies. *Sci Transl Med [Internet].* 2019;11:516.eaaz2686 [cited 2022 Jan 12]. Available from: DOI: 10.1126/scitranslmed.aaz2686.
 40. Liu Y, Cao W, Sun M, et al. Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities. *Emerg Microbes Infect.* 2020;9(1):194-206.
 41. Bradley T, Peppas D, Pedroza-Pacheco I, et al. RAB11FIP5 expression and altered natural killer cell function are associated with induction of HIV broadly neutralizing antibody responses. *Cell.* 2018;175:387-399.
 42. Duffloo J, Planchais C, Frémont S, et al. Broadly neutralizing anti-HIV-1 antibodies tether viral particles at the surface of infected cells. *Nat Commun [Internet].* 2022;13(1):630 [cited 2022 Jan 12]. Available from: DOI: 10.1038/s41467-022-28307-7.
 43. Beccari MV, Mogle BT, Sidman EF, et al. Ibalizumab, a novel monoclonal antibody for the management of multidrug-resistant HIV-1 infection. *Antimicrob Agents Chemother [Internet].* 2019; 63:e00110-19 [cited 2022 Jan 12]. Available from: <https://doi.org/10.1128/AAC.00110-19>.
 44. Wesley D. Kufel. Antibody-based strategies in HIV therapy. *Int J Antimicrob Agents [Internet].* 2020;56(6):106186 [cited 2022 Jan 25]. Available from: DOI: 10.1016/j.ijantimicag.2020.106186.
 45. Ahmad A, Rinaldo CR. A novel anti-HIV immunotherapy to cure HIV. *AIDS.* 2017;31(3):447-449.
 46. Vansant G, Bruggemans A, Janssens J, et al. Block-and-lock strategies to cure hiv infection. *Viruses [Internet].* 2020;12(1):84 [cited 2022 Jan 25]. Available from: DOI: 10.3390/v12010084.
 47. Gupta RK, Abdul-Jawad S, McCoy LE, et al. HIV-1 remission following CCR5Δ32/Δ32 haematopoietic stem-cell transplantation. *Nature.* 2019;568:244-248.
 48. Dash PK, Kaminski R, Bella R, et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. *Nat Commun [Internet].* 2019;10(1):2753 [cited 2022 Jan 25]. Available from: DOI: 10.1038/s41467-019-10366-y.
 49. Ahlenstiel CL, Symonds G, Kent SJ, et al. Block and lock HIV cure strategies to control the latent reservoir. *Front Cell Infect Microbiol [Internet].* 2020;10:424 [cited 2022 Jan 25]. Available from: DOI: 10.3389/fcimb.2020.00424.
 50. Dash PK, Kaminski R, Bellaet R, et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice. *Nat Commun [Internet].* 2019;10(1):2753 [cited 2022 Jan 25]. Available from: DOI: 10.1038/s41467-019-10366-y.
 51. Palermo E, Accioni C, Di Carlo D, et al. Activation of latent HIV-1 T cell reservoir with a combination of innate immune and epigenetic regulators. *J Virol [Internet].* 2019;93:e01194-19 [cited 2022 Jan 25]. Available from: DOI: 10.1128/JVI.01194-19.